Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress

被引：0

作者：

Yurou Chu

Xiangxiang Zhou

Xin Wang

机构：

[1] Cheeloo College of Medicine,Department of Hematology, Shandong Provincial Hospital

[2] Shandong University,Department of Hematology

[3] Shandong Provincial Hospital Affiliated to Shandong First Medical University,School of Medicine

[4] Shandong University,undefined

[5] Shandong Provincial Engineering Research Center of Lymphoma,undefined

[6] Branch of National Clinical Research Center for Hematologic Diseases,undefined

[7] National Clinical Research Center for Hematologic Diseases,undefined

[8] the First Affiliated Hospital of Soochow University,undefined

来源：

Journal of Hematology & Oncology | / 14卷

关键词：

Antibody-drug conjugates; Lymphoma; Immunotherapy; Clinical trials;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Antibody-drug conjugates (ADCs) are a promising class of immunotherapies with the potential to specifically target tumor cells and ameliorate the therapeutic index of cytotoxic drugs. ADCs comprise monoclonal antibodies, cytotoxic payloads with inherent antitumor activity, and specialized linkers connecting the two. In recent years, three ADCs, brentuximab vedotin, polatuzumab vedotin, and loncastuximab tesirine, have been approved and are already establishing their place in lymphoma treatment. As the efficacy and safety of ADCs have moved in synchrony with advances in their design, a plethora of novel ADCs have garnered growing interest as treatments. In this review, we provide an overview of the essential elements of ADC strategies in lymphoma and elucidate the up-to-date progress, current challenges, and novel targets of ADCs in this rapidly evolving field.

引用

共 1728 条

[31]

Marcus R(2018)DNA damaging agent-based antibody-drug conjugates for cancer therapy Antibody Therap 1 33-1353

[32]

Davies A(2013)Anthracycline based antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin's lymphoma are effective in cell lines resistant to auristatin based ADCs Can Res 73 4634-578

[33]

Ando K(2017)From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs) Angew Chem Int Ed 56 462-3599

[34]

Klapper W(2018)A DNA-interacting payload designed to eliminate cross-linking improves the therapeutic index of antibody-drug conjugates (ADCs) Mol Cancer Ther 17 650-3149

[35]

Opat S(2021)An Anti-CD22-seco-CBI-dimer antibody-drug conjugate (ADC) for the treatment of non-Hodgkin lymphoma that provides a longer duration of response than Auristatin-based ADCs in preclinical models Mol Cancer Ther 20 340-1067

[36]

Owen C(2017)Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix Int J Cancer 140 1670-3621

[37]

Phillips E(2021)Site-selective modification strategies in antibody-drug conjugates Chem Soc Rev 50 1305-78

[38]

Sangha R(2014)Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates Bioconjug Chem 25 569-1654

[39]

Schlag R(2019)Novel method for preparation of site-specific, stoichiometric-controlled dual warhead conjugate of FGF2 via dimerization employing sortase A-mediated ligation Mol Pharm 16 3588-510

[40]

Seymour JF(2019)New linker structures applied in glycosite-specific antibody drug conjugates Organ Chem Fron 6 3144-5849

← 1 2 3 4 5 6 7 8 9 10 →